We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Reference sheet · Cardiovascular · CPC catalog code ATPE-002
Composition figures above are derived arithmetically from the published sequence for the unmodified free peptide. Salt forms (commonly trifluoroacetate or acetate), amidation, and other modifications shift the observed mass — always reconcile against the current lot certificate of analysis.
Volumes for a 1 mg vial of Atriopeptin II (rat) at common working concentrations. Add solvent slowly down the vial wall and swirl — do not vortex or shake.
Reference standards in the Cardiovascular class are typically shipped as lyophilized powder and stored desiccated at −20 °C protected from light. Once reconstituted in bacteriostatic water or the assay-appropriate buffer, aliquot and store at −80 °C to minimize freeze–thaw cycles. Confirm handling requirements against your institutional biosafety and radiation protocols before use.
Atriopeptin II (rat) sits within the Cardiovascular research class (CPC reference ATPE-002). Cardiovascular peptides act on GPCRs and receptor systems in vascular smooth muscle, endothelium, and cardiac myocytes — modulating vasoconstriction, natriuresis, RAAS signaling, or ionotropic responses. Effects are typically measured in isolated vessel, Langendorff heart, or receptor-transfected cell assays.</ Investigators typically incorporate Atriopeptin II (rat) as a reference standard, tool ligand, or substrate in the assay contexts listed above. Radioligand-binding, IP-1 / cAMP HTRF, and organ-bath tension recordings are the standard readouts.
Atriopeptin II (rat) (CPC catalog code ATPE-002) is a synthetic cardiovascular research peptide in the cardiovascular category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.
Published and internal research programs use Atriopeptin II (rat) as a reference standard in cardiovascular workflows — for example, vascular reactivity in aortic ring and mesenteric bed preparations and renin–angiotensin–aldosterone system (raas) mechanistic studies. Human clinical evidence is not established.
No. Atriopeptin II (rat) is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.
In a cardiovascular workflow, Atriopeptin II (rat) is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Radioligand-binding, IP-1 / cAMP HTRF, and organ-bath tension recordings are the standard readouts.
Other reference standards in the same class — commonly cross-referenced during assay design and comparator selection.